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SUMMARY 
The main difficulty in the development of ATP antagonist kinase inhibitors is tar-
get specificity, since the ATP-binding motif is present in many proteins. We intro-
duce a strategy that has allowed us to identify compounds from a kinase inhibitor 
library that block the cyclin-dependent kinases responsible for regulating tran-
scription, i.e. CDK7 and especially CDK9. The screening cascade employs cellular 
phenotypic assays based on mitotic index and nuclear p53 protein accumulation. 
This permitted us to classify compounds into transcriptional, cell cycle, and mi-
totic inhibitor groups. We describe the characterisation of the transcriptional in-
hibitor class in terms of kinase inhibition profile, cellular mode of action, and se-
lectivity for transformed cells. A structural selectivity rationale was used to opti-
mise potency and biopharmaceutical properties and led to the development of a 
transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-
pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models. 
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Introduction 
Cyclin-dependent kinases (CDKs) are key cell cycle regulators and some also have 
regulatory functions in mRNA transcription at the level of RNA polymerase-II (RNAP-II) 
(Hirose et al., 2007). CDKs 1, 2, 7, 8, 9, and 11 have all been implicated in the phos-
phorylation of the C-terminal domain (CTD) of the largest RNAP-II subunit (Pinhero et 
al., 2004), but the most important ones are CDK7–cyclin H and CDK9–cyclin T 
(Ramanathan et al., 2001). The CTD contains repeating Tyr-Ser-Pro-Thr-Ser-Pro-Ser 
heptad sequences and the phosphorylation status of the Ser residues at positions 2 and 5 
has been shown to be important in the activation of RNAP-II. 
CDK7–cyclin H associates with the RING-finger protein MAT1 in the general transcrip-
tion factor IIH (TFIIH) and also acts as an activating kinase for other CDKs. Unlike other 
CDKs, CDK9 appears to function exclusively in transcriptional regulation. It forms com-
plexes with cyclin T1, T2, or K, which participate in the positive transcription elongation 
factor b (P-TEFb) (Michels et al., 2003). CDK9 phosphorylates both Ser-2 and Ser-5 of 
the CTD heptad (Pinhero et al., 2004), playing a predominant role during transcriptional 
elongation, in contrast to CDK7, which primarily phosphorylates Ser-5 of RNAP-II at the 
promoter as part of transcriptional initiation (Gomes et al., 2006). 
Overexpression of cyclins or suppression of CDK-inhibitory proteins (CDKIs) is fre-
quently observed in cancers and ectopic expression of CDKIs in tumour cells restores cell 
cycle control, leading to cell cycle arrest or apoptosis (Shapiro et al., 1999). However, it 
is now clear that many CDKs and cyclins associated with the cell cycle are functionally 
redundant, which suggests that targeting individual cell cycle CDKs may not be an opti-
mal therapeutic strategy (Barriere et al., 2007). The anticancer activity in preclinical 
models of the experimental CDK inhibitor drugs flavopiridol (alvocidib; Aventis/NCI) and 
R-roscovitine (seliciclib, CYC202; Cyclacel) are believed to result mostly from the tran-
scriptional inhibition mechanism (Fischer et al., 2005). Flavopiridol targets a number of 
CDKs and other kinases, and transcription inhibition caused by this compound in cancer 
cells was originally thought to be mediated by inhibition of CDK7 (Harper et al., 1998). 
Recent data, however, suggest that CDK9 inhibition plays a more important role (Chen et 
al., 2005). Treatment of cancer cells with flavopiridol results in inhibition of RNAP-II CTD 
phosphorylation, thus blocking transcription and inducing apoptosis by reducing mRNA 
levels of antiapoptotic proteins (Gojo et al., 2002). Selective induction of apoptosis in 
transformed cells by downregulation of antiapoptotic proteins through transcriptional 
CDK inhibition has also been demonstrated for R-roscovitine (MacCallum et al., 2005). 
Clinical trials results show flavopiridol monotherapy efficacy in haematological cancers, 
especially chronic lymphocytic leukaemia, which is particularly sensitive to transcriptional 
inhibition (Byrd et al., 2007). Many clinical and preclinical pan-CDK inhibitor compounds 
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are potent CDK9 inhibitors and their antiproliferative properties emanate from transcrip-
tional inhibition to a large extent (Joshi et al., 2007; Karaman et al., 2008; Wang et al., 
2008; Zhang et al., 2008). However, truly CDK7- and CDK9-selective compounds have 
not been reported to date (Wang et al., 2008). 
Here we report the results that have led to the identification of potent and selective 
new pharmacological CDK transcriptional inhibitors from our 2-anilino-4-(heteroaryl)-
pyrimidine kinase inhibitor compound library (Wang et al., 2004a; Wang et al., 2004b; 
Wu et al., 2003). We have developed a cell-based screening cascade that has enabled us 
effectively to delineate a pharmacophore subseries of compounds characterised by selec-
tive antiproliferative effects in tumour cells through transcriptional CDK inhibition. This 
cascade has permitted us to distinguish phenotypically and biochemically compounds that 
inhibit RNAP-II CDKs from those that act predominantly through inhibition of the cell cy-
cle CDKs (1, 2, 4), or the closely related mitotic aurora kinases. We use assays for mi-
totic index (MI), and p53 protein level measurements as a proxy measure for general 
transcriptional inhibition, for initial mechanistic compound classification, followed by more 
specific cell biological screens, such as caspase-3/7 activation assays, for more detailed 
compound mode-of-action analysis and classification (Griffiths et al., 2004; Griffiths et 
al., 2008; Wang et al., 2005; Wang et al., 2004a). 
Results 
Cellular phenotypic classification 
The effects of treatment of A2780 (ovarian), NCI-H460 (non-small cell lung), and A549 
(lung) tumour cell lines with compounds from our kinase inhibitor library were assessed 
using high through-put cell biological assays based on an automated microscopy system. 
Amongst these, MI and p53 protein level assays were found to be the most informative 
for classification of the library subgroups that target the cell cycle or transcription, re-
spectively. Based on time–course experiments, a 7-h treatment period with test com-
pounds was chosen to identify maximum effects on cell cycle or induction of p53 protein 
levels. p53 expression is regulated at the level of protein stability, and the increase in 
p53 protein levels after treatment with transcriptional inhibitors, including flavopiridol, is 
attributed to the downregulation of Mdm2 (Demidenko et al., 2004; Lu et al., 2001; 
Radhakrishnan et al., 2006), which is a well-established negative regulator of p53 protein 
(Michael et al., 2003). Compounds were typically screened using a concentration range of 
0.04–20 μM, which permitted assessment of both potency and phenotypic specificity. Ex-
amination of MI and p53 protein levels resulted in identification of three classes of com-
pounds: class-1 compounds decreased MI and induced high levels of nuclear p53 protein; 
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class-2 compounds increased MI, but had minimal effects on p53 protein levels; and 
class-3 compounds decreased MI and had minimal effects on p53 levels. Representatives 
of each class of compounds were further evaluated by enzymatic screening and cellular 
mode-of-action investigations. 
MI was used as an indicator of cell cycle status in unsynchronised proliferating cells. 
Figure 1a illustrates the response of A2780 cells and is representative across the concen-
tration range (the results from a primary MI and p53 screen of a set of 220 compounds is 
shown in Figure S1). Class-2 compounds, exemplified by a compound we have desig-
nated MKI-1 (for mitotic kinase inhibitor), delayed cells in mitosis and increased the 
overall MI of the cell population. Many of these compounds were subsequently identified 
as selective inhibitors of aurora kinases (data not shown, (Wang et al., 2010)). Class-1 
compounds such as 1, 3, 4, 6, 7, and 14 (Table 1) decreased MI, indicating a reduction 
in the number of cycling cells (Figure 1a) and increased the number of cells with high 
levels of nuclear accumulation of p53, typically with a 3- to 6-fold increase in A2780 
(Figure 1b). To determine if p53 induction was a result of a DNA damage response 
(Kastan et al., 1991), additional experiments were carried out using an independent 
DNA-damage response marker, phosphorylated histone H2AX (Rogakou et al., 1998). 
Treatment of MCF-7 cells with either doxorubicin, a classical DNA-damaging agent 
(Gewirtz, 1999), or 1 resulted in accumulation of p53 (Figure 1c). Treatment with 1 had 
no effect on the level of histone H2AX phosphorylation, which was increased substantially 
by doxorubicin (Figure S2). A likely mechanism of p53 accumulation for class-1 com-
pounds is reduction in the transcription and expression of Mdm2, the ubiquitin ligase re-
sponsible for degradation of p53 (Lu et al., 2001). Direct evidence for this mechanism 
was obtained after detailed investigations with compound 14 (see below). Nuclear p53 
protein levels were subsequently used as an indicator of general transcriptional inhibition 
and this correlated well with biochemical selectivity for CDK 7 and 9 inhibition (Figure 2). 
The third class of inhibitors, exemplified by the compounds designated CCI-1 and CCI-2 
(for cell cycle inhibitors) in Figure 1a & 1b, reduced MI but had no significant effect on 
p53 protein levels. These compounds were subsequently identified as selective cell cycle 
inhibitors, which cause stage-specific cell cycle arrest and prevent mitotic entry (Wang et 
al., 2005). 
CDK transcriptional inhibitors induce apoptosis in tumour cells 
Caspases 3 and 7 are the most crucial effector components of cell death pathways that 
culminate in the cleavage of a number of important cellular proteins (Fuentes-Prior et al., 
2004). We found that all of the compounds that we had identified as transcriptional CDK 
inhibitors (class-1) were capable of inducing a caspase-3/7 response in tumour cell lines, 
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including A2780, NCI-H460, MES-SA (uterine sarcoma) and HT-29 (colon adenocarci-
noma). When e.g. A2780 cells were treated with 1, 3, 4, 6, 7, and 14 for 24 h, substan-
tial induction of apoptosis was observed, typically a > 7-fold induction of caspase-3/7 ac-
tivation, compared to class-2 (MKI-1 & 2) and class-3 compounds (CCI-1 & 2), or con-
trols (Figure 1d). Caspase activation was only observed in transformed lines and not in 
the nontransformed foetal lung cell line WI-38, despite it being able to activate caspases 
3/7 in response to other classes of compounds. In all cases full induction of caspase ac-
tivity occurred over a narrow concentration range as an all-or-nothing response (Figure 
3a). Selective induction of apoptosis in transformed lines was confirmed by TUNEL of 
A2780 and WI-38 cells treated with compound 14. Cell cycle arrest was not detected, 
and TUNEL-positive cells originated from all stages of the cell cycle (Figure 3b). This was 
observed in all tumour cell lines tested where an intact caspase-3/7 pathway was pre-
sent, irrespective of mutant or wild-type p53 status. Class-1 compounds thus lead to 
apoptotic tumour cell death, and not to a stage-specific cell cycle block. 
CDK transcriptional inhibitor analogues: design and lead optimisation 
The 2-anilinopyrimidine compounds in Table 1 were prepared using procedures as de-
scribed (Wang et al., 2004a). Previously established SARs of a series of 2-anilino-4-
(thiazol-5-yl)pyrimidines with respect to CDK2 suggested the importance of substituents 
at C2 of the thiazole ring (Wang et al., 2004a). Introduction of amino functions in the 
context of either meta- or para-substituted anilines at the pyrimidine C2 resulted in in-
creased inhibition not only of CDK2, but also CDK9. CDK2-bound crystal structures of 
such compounds, e.g. 1, reveal that the thiazole C2-amino group interacts strongly with 
the Asp145 and Lys33 side chains and enhances the hydrophobic interaction of the thiazol-
4-yl methyl group with the Phe gatekeeper residue present in all CDKs (Phe80 in CDK2) 
(Wang et al., 2004a). In addition, a number of H-bonding interactions between the thia-
zole C2-alkylamino groups and Gln131 and Asp86 were also observed. Substitution of the 
thiazole C2 with bulkier groups such as phenyl, pyridyl, or other heterocycles, resulted in 
significantly reduced activity. The thiazol-4-yl methyl group was also found to be intoler-
ant of modification. Certain meta- or para-substitutions of the aniline ring were well tol-
erated and manipulation of these substituents led to a number of inhibitors possessing 
varying CDK selectivity profiles. Similar substituents in the ortho position abolished CDK-
inhibitory activity in all cases. 
Application of our screening cascade revealed that compounds with the transcriptional 
inhibitor phenotype predominantly inhibit CDK7 and CDK9 and show varying selectivity 
towards other CDKs, in particular CDK2 and CDK4, in enzymatic assays (Figure 2). A de-
rivative with a sulfonamide substituent at the aniline meta position and containing a me-
thylamino group at the thiazole C2 position (3) was found to be one of the most potent 
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transcriptional inhibitors in the class (Table 1). This compound also showed considerable 
potency against CDK2–cyclin E and CDK4–cyclin D1. Furthermore, it exhibited potent in 
vitro antitumour activity in a number of cancer cell lines. Replacement of the methyl-
amino with an ethylamino group at thiazole C2 afforded another comparatively selective 
inhibitor of CDK7 and CDK9 (2), although with reduced potency. This also resulted in a 
substantial reduction in antiproliferative activity against tumour cell lines. 
Methylation of the sulfonamide at the meta position of the aniline ring (4) also reduced 
CDKs 9, 2, and 4 activity somewhat compared to compound 3. Again this was accompa-
nied by an antiproliferative potency reduction. Analogue 5, which has a primary amino 
group at the thiazole C2 showed potency and selectivity profiles comparable to 4. Similar 
antiproliferative activity was observed for both compounds. Replacement of the sulfona-
mide of 3 with a methylsulfonyl function afforded another picomolar CDK9 inhibitor (6) 
that retained similar potency and selectivity with respect to CDKs 1, 2, and compared to 
3. The structural modification resulted in 10-fold lower activity against CDK4, however. 
As expected, 6 also displayed potent cytotoxicity in cells. Keeping the aniline portion of 6 
constant, but replacing the thiazole C2 substituent with the larger ethylamino group led 
to 7, with 5-fold reduced inhibition of CDK2 and 3-fold reduced inhibition of CDK9 com-
pared to 6. An ethyl group on the sulfonamide function (8), rather than the methylsul-
fonamide in 5, in the context of the thiazole C2 primary amine, resulted in slightly re-
duced potency throughout. 
In order to assess if targeting CDK9 alone would be sufficient for a compound to exhibit 
the transcriptional inhibitor phenotype, a number of selective CDK9 inhibitors were de-
signed. During lead optimisation we observed that introduction of bulky substituents at 
the meta position of the aniline resulted in unfavourable contacts with CDK1 and CDK2, 
whereas simple nonionisable alkyl functions at the para position were poorly tolerated in 
terms of CDK4 activity. Combination of such substitution patterns in individual com-
pounds led to the 4-methyl-3-(morpholine-4-sulfonyl)aniline derivatives 9 and 10. Both 
compounds were potent CDK9 inhibitors essentially devoid of activity against CDKs 1, 2, 
and 4, while retaining modest potency against CDK7. Application of 9 and 10 in the 
screening cascade revealed that both compounds clearly belonged to class-1. However, 
these compounds exhibited reduced cellular potency in comparison to other low nanomo-
lar Ki CDK9 inhibitors, which, in contrast, were potent against one or more additional 
CDKs. 
Structural modification by transposition of various sulfonamide or alkylsulfone functions 
from the meta to the para position of the aniline ring generally resulted in somewhat re-
duced potency against all CDKs except CDK2. Thus compound 11, although active 
against CDK9, inhibits CDK2 with almost 100-fold higher potency. However, having 
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achieved optimal CDK9 selectivity over CDK2 and CDK4 with compounds such as 9 and 
10, we turned our attention to CDK7 inhibition. We discovered that a number of com-
pounds with a 3H-thiazol-2-one (formula II in Table 1) rather than a thiazole (formula I) 
system at the pyrimidine C4 displayed enhanced potency against CDK7. This was espe-
cially true for analogues with a methylated thiazolone N3 and small electron-withdrawing 
aniline meta substituents, such as 12. Addition of a methyl group at the aniline para po-
sition again improved selectivity and also afforded our most potent CDK7 inhibitor com-
pound 13. 
As noted above, bulky aniline para substituents were not conducive to CDK9 selectivity. 
If, however, substituents containing an amino group that is charged at physiological pH 
were introduced at the para position in the context of the pyrimidinyl C4 thiazolone sys-
tem, both CDK7 and CDK9 potency was preserved, while maintaining selectivity with re-
spect to the other CDKs to some extent. The representative compound in this regard is 
14, which potently inhibits not only CDK7, but also CDK 9. CDKs 1, 2, 4, on the other 
hand, are inhibited at least 30-fold less potently. 
Compound 14 was also assessed for its selectivity in a panel of closely related non-CDK 
kinases. The results in Table S1 show that a range of kinases are inhibited by 14 at the 
mid-nanomolar to low micromolar IC50 level. Considering the fact that 14 is a mid-
picomolar IC50 CDK9 inhibitor and comparing with the non-CDK kinase inhibited most 
potently (VEGFR2 IC50 = 180 nM), this gives a selectivity of at least 400-fold. This com-
pound was also passed through a more extensive protein kinase panel that contains 
kinases representing most signalling pathways. The results again show that certain non-
CDK kinases are inhibited by 14, but at concentrations several orders of magnitude 
higher than those relevant to CDK7 and CDK9 inhibition (Figure S3). 
Compound 14 was further assessed for its biopharmaceutical properties (Table S2): it 
has low lipophilicity (logP = 1.1) and good aqueous solubility. Membrane permeability 
was moderate with a Papp value of 2.4 × 10
-6 cm/s by Caco-2 monolayer assay. Further-
more, 14 exhibited good in vitro metabolic stability with a half-life of 50 min and low in-
trinsic clearance in a liver microsome assay. Plasma protein binding was also low (36% 
unbound fraction). In order to confirm this, 14 was subjected to rat pharmacokinetic 
(PK) analysis following a single intravenous (iv) dose of 5 mg/kg or an oral (po) dose of 
50 mg/kg. Mean plasma concentrations were used to calculate the PK parameters (Table 
S2). The compound was found to be orally bioavailable (F = 70%) with a plasma half-life 
of ~ 5 h following po administration, and a large volume of distribution. The exposure 
values obtained show that multiples of in vitro bioactive concentrations can easily be 
achieved at good dose potency. 
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Structural rationale for potency and selectivity of transcriptional inhibitors 
In order to determine the basis for the selectivity and potency of CDK7 and CDK9 inhibi-
tors, we determined complex crystal structures with CDK2 for compounds 11 and 14 
(Figure 4a–d). Furthermore, we used published X-ray crystal structures of CDK7 (Lolli et 
al., 2004) and CDK9 (Baumli et al., 2008). 
The CDK7 and CDK9 selectivity of compound 14, which contains a piperazine substitu-
ent at the aniline para position, can be rationalised by the replacement of Lys89 in CDK2 
with smaller residues in CDK7 and CDK9 (Figure 4e & f). Our CDK2–14 complex crystal 
structure reveals that the bulky piperazine ring results in unfavourable contacts with the 
Lys89 side chain (Figure 4d). As a result, this side chain is forced to change position from 
that observed in apo- and ATP-bound CDK2 structures (Brown et al., 1999; Wu et al., 
2003), which is energetically unfavourable. On the other hand, modelling suggests that 
the residues corresponding to Lys89 in CDK2, i.e. Val100 in CDK7 or Gly112 in CDK9 can 
better accommodate the piperazine ring of 14. The complex structure of compound 14 
with CDK2 and homology modelling with other CDKs further indicate that electrostatic 
charge differences at the ATP-binding site of CDK1 and CDK2 with respect to CDKs 4, 7, 
and 9 play a significant role in the selectivity of this compound. Because CDKs 4, 7, and 
9 all have a nonionisable side chain in the Lys89 position, there is less repulsion with the 
positive charge on the piperazine ring (McInnes et al., 2004). 
For compound 11, which, unlike the piperazine ring of compound 14, has a flexible sul-
fonamide substituent, the situation is different. Here the p-anilino sulfonamide can be 
observed to make strong H-bonding interactions with the side-chain amino group of Lys89 
in CDK2 (Figure 4c). Similar interactions are not possible with CDK7 and CDK9, where 
small lipophilic residues are present in place of Lys89. 
The selectivity of the methylsulfone compounds 6 and 7 derives from differences in the 
residues that correspond to Gln131 in CDK2. This is Ala153 in CDK9, which is capable of 
forming favourable van-der-Waals contacts with the sulfone methyl groups. The increas-
ing CDK9 selectivity of compounds 4, 5, and 8–10, on the other hand, can be explained 
by the increase in steric bulk of the extensions of the sulfonamides at the aniline meta 
position. As we have shown, compounds with small aniline meta substituents – e.g. the 
nitro derivative 1, adopt CDK2 binding poses with two distinct aniline orientations (Wang 
et al., 2004a). Modelling shows that unfavourable intramolecular interactions of the sul-
fonamide extensions in compounds 4, 5, and 8–10 with the thiazole/thiazolone head 
groups force the aniline rings to project towards the position occupied by Lys89 in CDK2, 
resulting in unfavourable contacts. From the crystal structures of CDK7 and CDK9 it is 
apparent that the region around Lys88-Lys89 (in the CDK2 context) is considerably more 
open in CDK7 – and especially in CDK9 – due to the presence of the smaller side chains 
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of the corresponding residues (Glu99-Val100 and Ala111-Gly112 in CDK7 and CDK9 respec-
tively). 
Cellular mode of action of compound 14  
In vitro antiproliferative activity. On the basis of its in vitro kinase potency, selectivity, 
and pharmaceutical properties, a detailed study of the cellular mode of action of 14 was 
carried out. It was screened against a panel of human leukaemia and solid tumour cell 
lines (Table S3). A broad spectrum of in vitro antitumour activity was observed, with an 
average IC50 value of 0.3 μM. There was no selectivity towards cell line types based on 
p53, p21, p16, or pRb status. Selectivity towards transformed versus untransformed cell 
lines was observed: 14 was 20- and 40-fold less potent against foetal lung fibroblast 
lines WI-38 and IMR-90, respectively, compared to the tumour cell lines examined. 
RNAP-II CTD phosphorylation and p53 induction. In accordance with the biochemical 
enzyme inhibition data showing 14 to be a potent inhibitor of CDK7 and CDK9, the phos-
phorylation of both Ser-2 and Ser-5 of the RNAP-II CTD was reduced significantly after 3 
h in A2780, with WI-38 cells showing a similar response at 24 h (Figure 5). Protein levels 
of p53 were induced at early time points since p53 is regulated at the translational level, 
but p21 levels, normally upregulated by p53-dependent transcription, did not rise due to 
inhibition of transcription by 14. 
Reduction of antiapoptotic protein levels. At 3 h, Mcl-1 levels were reduced in A2780 
cells. After 24 h, A2780 and WI-38 cells both showed a reduction in antiapoptotic pro-
teins XIAP, Mcl-1, and survivin (Figure 5). A2780 cells showed a greater reduction in lev-
els of survivin and XIAP than WI-38 cells. Both cell lines showed reductions in Mcl-1. It is 
interesting to note that A2780 cells possess much greater levels of Mcl-1 than WI-38 in 
untreated samples. 
Selective induction of apoptosis in transformed cells. Apoptosis is induced in A2780 
cells, as detected by caspase-3/7 assay, at concentrations of 0.31 μM 14 and above. WI-
38 cells, however, were completely insensitive even at 10 μM 14 (Figure 3a), despite 
showing sensitivity to mechanistically unrelated kinase inhibitor compounds. This result 
confirms the selectivity for transformed cells seen in the MTT proliferation assay (Table 
S3). TUNEL analysis, in conjunction with DNA staining, showed that 50% of cells were 
TUNEL-positive after 24 h with 2 μM 14 (Figure 3b). These apoptotic cells were observed 
in all cell cycle compartments, suggesting that this class of inhibitor causes cell death at 
each stage of the cell cycle and does not lead to a stage-specific cell cycle block. A reduc-
tion in the levels of antiapoptotic proteins occurred in both transformed (A2780) and un-
transformed (WI-38) cell lines. However, PARP cleavage (Figure 5) only occurred in the 
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A2780 cell line, suggesting that antiapoptotic proteins may play a less important role in 
the untransformed cells than in the oncogenically transformed cells. 
Selective CDK9–cyclin T inhibition also induces the transcriptional-type response in 
cells. Compounds 3, 10, and in particular, compound 9, showed greater selectivity for 
CDK9 over CDK7. Figure 2 shows that at the concentrations of compounds needed to in-
duce cellular cytotoxicity, the contribution of CDK7 inhibition is negligible. From the 
screening cascade these compounds belonged to class-1 and further analysis of key cel-
lular proteins showed a significant reduction in RNAP-II CTD Ser-2 phosphorylation, a 
slightly weaker reduction in Ser-5 phosphorylation, an induction of p53, and a reduction 
in Mcl-1 levels after 3 h exposure in A2780 cells (Figure S4). These responses are consis-
tent with that shown by 14, an approximately equipotent CDK7 and CDK9 inhibitor. Like 
14, the CDK9-specific inhibitors 3, 9, and 10 induced apoptosis selectively in trans-
formed cells (Table S4). 
In vivo anti-tumour activity of compound 14 
Compound 14 was evaluated for in vivo antitumour activity using a P388/0 murine leu-
kaemia survival model (Marsh et al., 1985). When dosed twice daily for 10 d with 14, 
animals experienced an increase in life span of 68, 45, and 36% at doses of 30, 20 and 
13 mg/kg/dose, respectively (P < 0.0001; Figure S5). The treated animals suffered no 
weight loss compared to animals receiving vehicle only and the maximum tolerated dose 
(MTD) of 14 was not achieved in this experiment, indicating a good therapeutic margin. 
Compound 14 also demonstrated antitumour activity in a murine xenograft solid tu-
mour model using the human colorectal Colo-205 cell line. As a positive control 5-
fluorouracil (5-FU), the chemotherapy drug most commonly used in the clinic for colorec-
tal cancer, was included on an optimal iv dosing regimen at the MTD. The test compound 
14 was administered by either the intraperitoneal (ip) or oral route (Figure S6). When 
given at 50 mg/kg ip every day for 8 days, 14 produced a specific tumour growth delay 
of 10.5 days (P < 0.05). Similarly, 14 was active and well tolerated when given by the 
same schedule at 100 mg/kg po, resulting in a tumour growth delay of 7 days (P < 
0.05). On the last evaluable day the tumour versus control ratios (T/C) were below 40% 
at the top dose by both administration routes. By comparison, 5-FU was considerably 
less active at its MTD of 50 mg/kg, given every 4 days for 4 treatments, and only yielded 
a tumour growth delay of 1 day. 
Discussion 
The work presented here explores the biomedical rationale for the development of phar-
macological inhibitors of transcription. This effect is achieved with kinase inhibitors that 
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target predominantly CDK9–cyclin T1 and is further explored by studying the effects of 
simultaneously inhibiting CDK7 and CDK2, additional CDKs thought to be responsible for 
the regulation of RNAP-II activity through phosphorylation of its CTD. 
The current model of RNAP-II regulation postulates a sequence in which CDK7 first 
phosphorylates CTD Ser-5 residues as part of transcription initiation (Sims et al., 2004). 
Subsequent dephosphorylation of Ser-2, and then phosphorylation of Ser-2 residues by 
CDK9 (Zhou et al., 2000) is necessary for the transition to RNA elongation (Price, 2000). 
Detailed analysis of CTD phosphorylation by CDKs 7, 8 and 9 (Ramanathan et al., 2001) 
have shown all three kinases to be capable of phosphorylating Ser-5, but not Ser-2, of a 
CTD peptide in vitro, despite evidence of in vivo phosphorylation at both Ser-2 and Ser-5 
residues. This seems to correlate with the concept of stepwise phosphorylation, with Ser-
5 phosphorylation being the initiating event, while Ser-2 becomes phosphorylated only 
after other criteria are met. Another study has highlighted the nonuniformity of CTD 
phosphorylation, showing that each of the three kinases produces different patterns of 
phosphorylation of the CTD, but that only CDK7 efficiently produces hyperphosphorylated 
substrates (Pinhero et al., 2004). These studies suggest that CTD phosphorylation is 
regulated in a complex manner, with changes in substrate specificity depending upon the 
transcriptional state of the complex and the accessibility of different regions of the CTD. 
Each of our transcriptional-type inhibitor compounds is capable of reducing the phos-
phorylation of Ser-2 and Ser-5 of the CTD of RNAP-II. There is a differential response in 
the phosphorylation state of Ser-2 and Ser-5, with quicker and more pronounced 
dephosphorylation of Ser-2 over Ser-5. At this stage we cannot conclusively demonstrate 
kinase specificity for each site as this difference may be due to different phosphatase ac-
tivities or site accessibility. However, compounds 3, 9 and 10, that we postulate to pos-
sess no appreciable CDK7 activity at the concentrations used to elicit a cytotoxic IC50 re-
sponse (Figure 2), can still cause a reduction in Ser-2 phosphorylation after 3 h and initi-
ate events that lead to the subsequent induction of apoptosis. This data lends support to 
the hypothesis of CDK9 targeting the Ser-2 site of RNAP-II and that inhibition of CDK9 is 
sufficient to inhibit transcription. 
The transcriptional activity of RNAP-II is required in all cells and inhibition of RNAP-II 
may thus not immediately present itself as a rational target for cancer therapeutics. 
However, transformed cells have a greater requirement for enhanced transcriptional ac-
tivity. Firstly, their increased rate of proliferation necessitates increased protein produc-
tion. Secondly, cells are genetically predisposed to enter into programmed cell death 
upon oncogenic stimulation, but a few may be able to transform into an apoptosis-
resistant, rapidly proliferating state by a number of means. One way of avoiding apop-
totic death is the increased production of antiapoptotic proteins in order to counteract the 
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presence of the proapoptotic proteins induced by the initial transforming event 
(Koumenis et al., 1997). The cancer cell achieves a new balance, but at the expense of 
continuously increased production of these antiapoptotic proteins, many of which have 
short half-lives at both the mRNA and protein levels. The fully transformed cell is thus 
committed to a strategy of increased protein production and therefore increased tran-
scription in order to maintain the status quo of cell survival over programmed cell death. 
The increased production of antiapoptotic proteins in transformed cells is well docu-
mented (Liston et al., 2003; Schimmer, 2004). For example, elevated levels of survivin, 
XIAP, cIAP1, and cIAP2 have been shown in human prostate cancers and in prostate tis-
sues from transgenic mice expressing SV40 large T antigen (Krajewska et al., 2003). 
Survivin is highly expressed in many transformed cells  but is rarely detected in normal 
adult tissues (Zangemeister-Wittke et al., 2004). Mcl-1 is a member of the anti-apoptotic 
Bcl-2 family (Cory et al., 2003) whose expression decreases when cells undergo apop-
tosis (Iglesias-Serret et al., 2003). Increased Mcl-1 protein levels have been reported in 
a number of tumour samples (Khoury et al., 2003; Song et al., 2005), and a difference in 
expression may be observed in the control lanes of A2780 and WI-38 (Figure 5). 
We show that as a result of decreased transcription, the expression levels of a number 
of highly expressed, short half-life, antiapoptotic proteins such as Mcl-1, survivin, and 
XIAP decline rapidly in both transformed and untransformed cell lines. We demonstrate 
that although the primary events of dephosphorylation of RNAP-II, induction of p53, and 
downregulation of antiapoptotic proteins, is consistent across transformed and untrans-
formed lines, the ultimate fate of the cell is governed by its reliance upon antiapoptotic 
proteins for continued survival. This results in a selective apoptotic response, demon-
strated by strong induction of caspase-3/7 activity, PARP cleavage, and appearance of 
TUNEL-positive cells in transformed cell lines only. 
The induction of p53, a protein whose expression is tightly regulated at the posttransla-
tional level by its association with Mdm2, itself a short half-life protein that is affected by 
reduced transcriptional activity, may contribute to the apoptotic response. p53 may 
translocate to the mitochondria and induce apoptosis through its direct interaction with, 
and activation of proapoptotic proteins such as Bax (Arima et al., 2005). However, as we 
see no differential sensitivity between p53 wild-type and p53 mutant or null cells in our 
cytotoxicity assays and have demonstrated that the response is not part of a DNA dam-
age response, we conclude that this effect is not integral to compound mode of action 
and we simply utilise this induction as part of our screening cascade. The increase in p53 
levels is not accompanied by increased p21 levels, (a protein normally regulated by p53 
activity), a response in keeping with transcriptional inhibition. 
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The work described here highlights our current understanding of transcriptional-type 
CDK inhibitors and demonstrates how this knowledge can be adapted to provide an effi-
cient screening cascade for the identification of such compounds. We have profiled a 
number of compounds with the ability to reduce the phosphorylation of Ser-2 and Ser-5 
of the CTD of RNAP-II through inhibition of CDK9–cyclin T and CDK7–cyclin H and selec-
tively kill transformed cells as a result of this inhibition. Our work shows that although 
both transformed and untransformed cells show a similar reduction in antiapoptotic pro-
teins due to inhibition of RNAP-II CTD phosphorylation, untransformed WI-38 lung fibro-
blasts do not undergo apoptosis, thus demonstrating a differential response to the down-
stream events that cause transformed cells to undergo apoptosis through the caspase 
pathway. In vivo experiments have also demonstrated a good tolerance for compound 14 
and significant increases in life span and antitumour activity in mouse models. We thus 
conclude that an untransformed cell, with intact checkpoints, low oncogenic stress, and 
lower levels of apoptotic proteins may have a significant tolerance towards transient inhi-
bition of RNAP-II activity, whereas the equivalent transformed cell would be much more 
susceptible to this type of inhibition and undergo a caspase-induced apoptotic death. 
Experimental procedures 
Synthesis and compound characterisation 
Preparation of [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-
amine (1) was described (Wang et al., 2004a). Compounds 2–10 were prepared in the 
same manner. Details are provided as Supplemental Experimental Procedures. 
Cell-based assays 
Mitotic index assay. MI was determined by an automated fluorescence microscopy 96-
well plate assay using the Cellomics Arrayscan Mitotic Index HitKit protocol (Cellomics 
Inc.). Briefly, cells were plated at 104 cells per well and incubated for 18 h at 37 °C. Test 
compounds were added and cells were incubated for the appropriate time before a 15-
min fixation in 3.7% formaldehyde in PBS. Cells were permeabilised in PBS with 0.2% 
triton X-100 for 15 min, washed, and incubated with a primary antibody that specifically 
recognises a mitotic epitope (rabbit anti-phosphoserine-10 histone-H3, Upstate 06-570). 
After incubation with a secondary FITC-conjugated anti-rabbit antibody and Hoechst 
33258 dye, cells were washed and analysed using the Cellomics Arrayscan II automated 
fluorescent microscopy system to detect nuclear fluorescent staining. Data for 2,000 cells 
per well were collected and the Cellomics mitotic index algorithm used to calculate mi-
totic index (MI; percentage of cell nuclei stained with the mitosis-specific antibody versus 
total cell nuclei stained with Hoechst 33258 dye). A similar assay was carried out for DNA 
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damage by substituting a mouse antibody specific for the DNA damage marker histone 
H2AX (Upstate 17-327A) as the primary antibody and FITC-conjugated anti-mouse anti-
body as secondary antibody. 
p53 Stabilisation assay. Cells were plated at 104 cells per well and incubated for 18 h at 
37 °C. Test compounds were added and cells were incubated for the appropriate time 
before a 3-min fixation in cold (-20 °C) 50:50 v/v methanol/acetone. The fixed cells were 
dried briefly then washed with PBST (PBS, 0.1% triton X-100) and incubated with pri-
mary CM-1 rabbit anti-human p53 antiserum (Midgley et al., 1992) diluted 1:1,000. After 
incubation with a secondary Alexa Fluor 488 goat anti-rabbit antibody (Molecular Probes, 
A11008) and Hoechst dye, the cells were washed and analysed using the Cellomics Ar-
rayscan II automated fluorescent microscopy system to detect nuclear fluorescent stain-
ing. Data for 2,000 cells per well were collected and the Cellomics mitotic index algorithm 
used to calculate percentage of cell nuclei stained with p53-specific antibody versus total 
cell nuclei stained with Hoechst. 
MTT cytotoxicity assays. Standard MTT (thiazolyl blue; 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assays were performed after 72 h treatment with test 
compounds (Haselsberger et al., 1996). 
Determination of apoptosis. Apoptosis was determined by either a terminal deoxynucleo-
tidyl transferase-mediated nick end labelling (TUNEL) assay (ApoDirect BD), following 
manufacturer’s instructions, or by caspase-3/7 assay (Caspase-Glo 3/7 assay, Promega), 
following manufacturer’s instructions, with cells seeded at 10,000 per well of a 96-well 
plate in a total volume of 100 μL medium per well. Assays were performed 24 h after test 
compound addition. Detection reagent (100 μL) was added directly to each 100-μL sam-
ple and readings were taken after a further 30 min incubation at room temperature. 
Western blot analysis. Total protein cell lysates (10 μg) were run on SDS-PAGE (4-12% 
gradient) gels (Novex) under reducing conditions. The separated proteins were trans-
ferred to membranes and were probed with antibodies specific for pRb (BD), 249/252 
pRb (BioSource), RNAP-II, RNAP-II Ser-2, RNAP-II Ser-5 (Covance), p53 (Oncogene ab-
6), p21, PARP, Mcl-1 (Santa Cruz), XIAP, survivin (Novus), and actin (Sigma). 
In vitro kinase assays 
Details for the cloning, expression, and purification of His-tagged CDK9/Cyclin T1 are 
provided as Supplemental Experimental Procedures. 
Kinase assays. CDK and other kinase assays were carried out as previously described 
(Wang et al., 2004a). IC50 values were calculated from 10-point dose-response curves 
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and apparent inhibition constants (Ki) were calculated from the IC50 values and appropri-
ate Km (ATP) values for the kinases in question (Cheng et al., 1973). 
Pharmacology 
Screening, biopharmaceutical profiling, PK determinations, and evaluation of anti-tumour 
efficacy of test compounds are described in the Supplemental Experimental Procedures. 
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Table 1. Structures and biological activity of selected CDK inhibitors. 
No. 
Structure 
N
N
N
H
R2
R3
S
N
R1
N
N
N
H
R2
R3
S
N
OR1
I II  
Formula R1 R2 R3 
1 I NH2 NO2 H 
2 I NHEt SO2NH2 H 
3 I NHMe SO2NH2 H 
4 I NHMe SO2NHMe H 
5 I NH2 SO2NHMe H 
6 I NHMe SO2Me H 
7 I NHEt SO2Me H 
8 I NH2 SO2NHEt H 
9 I NHMe SO2-morpholine Me 
10 I NH2 SO2-morpholine Me 
11 II Me H SO2NH(CH2)2OMe 
12 II Me CN H 
13 II Me NO2 Me 
14 II Me H Piperazine 
No. 
Kinase inhibition, Ki (nM) 72-h MTT, IC50 (nM) 
CDK1 CDK2 CDK4 CDK7 CDK9 A2780 MES-SA 
1 73 ± 31 < 1 19 ± 17 73 ± 5 4.6 ± 5.2 41 ± 2 140 ± 13 
2 691 ± 81 403 ± 29 132 ± 53 56 ± 24 4.5 ± 1.4 666 ± 106 1,608 ± 235 
3 67 ± 11 2.4 ± 1.3 9.1 ± 2.9 25 ± 7 0.80 ± 0.79 12 ± 5 76 ± 10 
4 334 ± 3 33 ± 1 20 ± 7 107 ± 71 4.3 ± 2.1 178 ± 44 278 ± 75 
5 233 ± 32 26 ± 3 163 ± 73 127 ± 48 4.3 ± 1.8 205 ± 156 428 ± 45 
6 86 ± 63 1.6 ± 0.2 94 ± 4 91 ± 13 0.29 ± 0.27 87 ± 2 93 ± 15 
7 > 500 7.6 ± 1.5 139 ± 23 47 ± 24 0.96 ± 0.14 101 ± 2 50 ± 15 
8 660 ± 353 47 ± 16 391 ± 50 193 ± 13 5.9 ± 1.5 332 ± 13 425 ± 65 
9 > 500 > 500 > 500 3,469 ± 1,526 6.7 ± 3.0 760 ± 336 370 ± 43 
10 > 500 > 500 > 500 304 ± 87 8.5 ± 1.3 692 ± 35 169 ± 45 
11 4.1 ± 0.8 0.11 ± 0.05 > 500 940 ± 55 14 ± 2 221 ± 75 98 ± 10 
12 399 ± 16 0.52 ± 0.11 102 ± 53 6.8 ± 3.0 1.9 ± 2.3 216 ± 20 367 ± 30 
13 3.0 ± 0.5 28 ± 3 60 ± 18 0.56 ± 0.13 5.9 ± 3.3 34 ± 1 126 ± 30 
14 449 ± 48 149 ± 40 68 ± 28 2.3 ± 0.2 0.38 ± 0.27 131 ± 9 150 ± 16 
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Figure 1. Identification of CDK transcriptional inhibitors by cell-based assays in 
A2780 cancer cells. Cells were treated with test compounds or assay diluent only (con-
trol) at 0.63 µM (a, b) or the concentrations indicated (c) for 7 h (a–c) or 24 h (d). MI 
was measured by determining the percentages of phospho-histone-H3 positive cells (a). 
Nuclear accumulation of p53 was assessed by immunofluorescent staining (b). Transcrip-
tion inhibitors induce a time-dependent increase in p53 protein (c) and an apoptotic sig-
nal through activation of caspases-3/7 (d). 
Figure 2. Cellular CDK selectivity. For each test compound the antiproliferative 72-h 
MTT assay IC50 value against A2780 cells was divided by the Ki values against individual 
CDKs (determined in biochemical kinase assays) and the ratios were plotted. A low ratio 
(ratios of ≤ 1 are shown as unity for the sake of clarity) indicates that antiproliferative 
activity is unlikely to be due to inhibition of the CDK in question. It is apparent that CDK9 
inhibition is important for all transcriptional inhibitors (1–10 & 14). No other kinase 
tested shows such a correlation. Of the nontranscriptional inhibitors, 11, 12, and CCI-2 
show potentially significant cellular inhibition of CDK9 but these compounds also show 
strong activity against other kinases. 
Figure 3. Selective induction of apoptosis in transformed cells. (a) Caspase-3/7 
activation assays show 14 selectively to induce caspase activation in the transformed 
A2780 cell line but not in the nontransformed WI-38 line. Treatment with CCI-3 demon-
strates caspase induction in both cell lines. (b) Flow cytometric analysis was performed 
and cell death (by TUNEL assay gating; ordinate) was correlated with cell cycle stage (by 
DNA content gating; abscissa). Cells were treated with assay diluent only (control) or 
with 2 μM compound 14 (treated) for 24 h. Treatment with 14 (2 μM) resulted in 31% 
TUNEL-positive A2780 cells corresponding to all cell cycle phases, whereas similar treat-
ment of WI-38 cells gave rise to only 4.8% TUNEL-positive cells. 
Figure 4. Structural basis for compound CDK selectivity. Electron density (grey 
mesh) and two plausible binding conformations (green and cyan CPK sticks) each for 14 
(a) and 11 (b) (contoured at 1.2 and 1.0 σ, respectively) in the complex crystal struc-
tures with CDK2 (grey CPK surface). Observed interactions of 11 (c) and 14 (d) with the 
ATP-binding site of CDK2 (grey), corresponding residues from an aligned structure of a 
catalytically competent CDK2-cyclin A-ATP/Mg structure are shown (PDB # 1QMZ; 
salmon). Broken lines indicate energetically favourable (magenta) and unfavourable 
(black) interactions (distances are indicated in Å). Superimposition of the CDK2–14 com-
plex (grey) with a CDK9 (PDB # 3BLR; salmon; e) and a CDK7 crystal structure (PDB # 
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1UA2; salmon; f). The RMSD for the alignment of the CDK9 and CDK7 with the CDK2-14 
coordinates (all atoms / ATP-binding site) was 2.39 Å / 0.78 Å and 1.65 Å / 0.92 Å, re-
spectively. For data collection and refinement statistics of the X-ray crystal structure 
complexes of CDK2 with compounds 11 and 14 refer to Table S5. 
Figure 5. Status of key cellular proteins following treatment with compound 14. 
After exposure of A2780 cells to 14 (a) CTD phosphorylation of Ser-2 and Ser-5 of 
RNAP-II is significantly reduced after 3 h. p53 levels have increased and levels of the an-
tiapoptotic protein Mcl-1 have been reduced, whilst XIAP remains fairly constant at early 
time points. There is no reduction in phosphorylation of pRb at the 249/252, 780 or 821 
sites. After 24 h treatment with 14 (b) both the transformed A2780 and untransformed 
WI-38 cell lines show a similar primary response. There is a reduction in phosphorylation 
of the CTD of RNAP-II at Ser-2 and Ser-5, an increase in p53, and a decrease in each of 
the antiapoptotic proteins XIAP, Mcl-1, and survivin. Only A2780 cells show cleavage of 
PARP, however, suggesting that apoptosis has been initiated in these cells. 
 
 19 
References 
Arima, Y., Nitta, M., Kuninaka, S., Zhang, D., Fujiwara, T., Taya, Y., Nakao, M., and 
Saya, H. (2005). Transcriptional Blockade Induces p53-dependent Apoptosis Associated 
with Translocation of p53 to Mitochondria. J. Biol. Chem. 280, 19166-19176. 
Barriere, C., Santamaria, D., Cerqueira, A., Galan, J., Martin, A., Ortega, S., Malumbres, 
M., Dubus, P., and Barbacid, M. (2007). Mice thrive without Cdk4 and Cdk2. Mol. Oncol. 
1, 72-83. 
Baumli, S., Lolli, G., Lowe, E.D., Troiani, S., Rusconi, L., Bullock, A.N., Debreczeni, J.E., 
Knapp, S., and Johnson, L.N. (2008). The structure of P-TEFb (CDK9/cyclin T1), its 
complex with flavopiridol and regulation by phosphorylation. EMBO J. 27, 1907-1918. 
Brown, N.R., Noble, M.E., Endicott, J.A., and Johnson, L.N. (1999). The structural basis 
for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. 
Cell Biol. 1, 438-443. 
Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B., Moran, M., Blum, 
K.A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L.J., Johnson, A.J., Lucas, 
D.M., Heerema, N.A., Lozanski, G., Young, D.C., Suarez, J.R., Colevas, A.D., and Grever, 
M.R. (2007). Flavopiridol administered using a pharmacologically derived schedule is 
associated with marked clinical efficacy in refractory, genetically high-risk chronic 
lymphocytic leukemia. Blood 109, 399-404. 
Chen, R., Keating, M.J., Gandhi, V., and Plunkett, W. (2005). Transcription inhibition by 
flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106, 2513-
2519. 
Cheng, Y.-C., and Prusoff, W.H. (1973). Relation between the inhibition constant IK1) 
and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an 
enzymic reaction. Biochem. Pharmacol. 22, 3099-3108. 
Cory, S., Huang, D.C.S., and Adams, J.M. (2003). The Bcl-2 family: roles in cell survival 
and oncogenesis. Oncogene 22, 8590-8607. 
Demidenko, Z.N., and Blagosklonny, M.V. (2004). Flavopiridol induces p53 via initial 
inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant 
cells to tumor necrosis factor. Cancer Res. 64, 3653-3660. 
Fischer, P.M., and Gianella-Borradori, A. (2005). Recent progress in the discovery and 
development of CDK inhibitors. Expert Opin. Investig. Drugs 14, 457-477. 
Fuentes-Prior, P., and Salvesen, G.S. (2004). The protein structures that shape caspase 
activity, specificity, activation and inhibition. Biochem. J. 384, 201-232. 
Gewirtz, D.A. (1999). A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. 
Pharmacol. 57, 727-741. 
Gojo, I., Zhang, B., and Fenton, R.G. (2002). The Cyclin-dependent Kinase Inhibitor 
Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional 
Repression and Down-Regulation of Mcl-1. Clin. Cancer Res. 8, 3527-3538. 
Griffiths, G., Midgley, C., Grabarek, J., Cooper, M., Glover, D., Ingram, L., Jackson, W., 
Meades, C., Mezna, M., O'Boyle, J., Wood, G., Yuill, R., Lane, D.P., Jackson, R., Fischer, 
 20 
P.M., and Wang, S. (2004). Identification and characterization of kinase inhibitors that 
inhibit CDK2, CDK7 and CDK 9 activities, induce p53 and result in reduced proliferation 
and induction of apoptosis of human tumor cells. Proc. Am. Assoc. Cancer Res. 45, Abs. 
837. 
Griffiths, G., Scaerou, F., Midgley, C., McClue, S., Tosh, C., Jackson, W., MacCallum, D., 
Wang, S., Fischer, P., Glover, D., and Zheleva, D. (2008). Anti-tumor activity of CYC116, 
a novel small molecule inhibitor of Aurora kinases and VEGFR2. Proc. Am. Assoc. Cancer 
Res. 49, Abs. 5644. 
Harper, J.W., and Elledge, S.J. (1998). The role of Cdk7 in CAK function, a retro-
retrospective. Genes Dev. 12, 285-289. 
Haselsberger, K., Peterson, D.C., Thomas, D.G., and Darling, J.L. (1996). Assay of 
anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein 
binding dye assay in short-term cultures derived from human malignant glioma. Anti 
Cancer Drugs 7, 331-338. 
Hirose, Y., and Ohkuma, Y. (2007). Phosphorylation of the C-terminal domain of RNA 
polymerase II plays central roles in the integrated events of eucaryotic gene expression. 
J. Biochem. 141, 601-608. 
Iglesias-Serret, D., Pique, M., Gil, J., Pons, G., and Lopez, J.M. (2003). Transcriptional 
and translational control of Mcl-1 during apoptosis. Arch. Biochem. Biophys. 417, 141-
152. 
Joshi, K.S., Rathos, M.J., Joshi, R.D., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, 
B., and Sharma, S. (2007). In vitro antitumor properties of a novel cyclin-dependent 
kinase inhibitor, P276-00. Mol. Cancer Ther. 6, 918-925. 
Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., 
Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., Faraoni, R., Floyd, M., Hunt, J.P., 
Lockhart, D.J., Milanov, Z.V., Morrison, M.J., Pallares, G., Patel, H.K., Pritchard, S., 
Wodicka, L.M., and Zarrinkar, P.P. (2008). A quantitative analysis of kinase inhibitor 
selectivity. Nat. Biotechnol. 26, 127-132. 
Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. (1991). 
Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 
6304-6311. 
Khoury, J.D., Medeiros, L.J., Rassidakis, G.Z., McDonnell, T.J., Abruzzo, L.V., and Lai, R. 
(2003). Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade 
morphology, a high proliferative state, and p53 overexpression. J. Pathol. 199, 90-97. 
Koumenis, C., and Giaccia, A. (1997). Transformed cells require continuous activity of 
RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell. Biol. 17, 7306-7316. 
Krajewska, M., Krajewski, S., Banares, S., Huang, X., Turner, B., Bubendorf, L., 
Kallioniemi Olli, P., Shabaik, A., Vitiello, A., Peehl, D., Gao, G.-J., and Reed John, C. 
(2003). Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. 
Cancer Res. 9, 4914-4925. 
Liston, P., Fong, W.G., and Korneluk, R.G. (2003). The inhibitors of apoptosis: there is 
more to life than Bcl2. Oncogene 22, 8568-8580. 
Lolli, G., Lowe, E.D., Brown, N.R., and Johnson, L.N. (2004). The Crystal Structure of 
Human CDK7 and Its Protein Recognition Properties. Structure 12, 2067-2079. 
 21 
Lu, W., Chen, L., Peng, Y., and Chen, J. (2001). Activation of p53 by roscovitine-
mediated suppression of MDM2 expression. Oncogene 20, 3206-3216. 
MacCallum, D.E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., 
Lane, D.P., and Green, S.R. (2005). Seliciclib (CYC202, R-roscovitine) induces cell death 
in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and 
down-regulation of Mcl-1. Cancer Res. 65, 5399-5407. 
Marsh, J.C., Shoemaker, R.H., and Suffness, M. (1985). Stability of the in vivo P388 
leukemia model in evaluation of antitumor activity of natural products. Cancer Treat. 
Rep. 69, 683-685. 
McInnes, C., Wang, S., Anderson, S., O'Boyle, J., Jackson, W., Kontopidis, G., Meades, 
C., Mezna, M., Thomas, M., Wood, G., Lane, D.P., and Fischer, P.M. (2004). Structural 
determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. 
Chem. Biol. 11, 525-534. 
Michael, D., and Oren, M. (2003). The p53-Mdm2 module and the ubiquitin system. 
Semin. Cancer Biol. 13, 49-58. 
Michels, A.A., Nguyen, V.T., Fraldi, A., Labas, V., Edwards, M., Bonnet, F., Lania, L., and 
Bensaude, O. (2003). MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a 
transcription-dependent manner. Mol. Cell. Biol. 23, 4859-4869. 
Midgley, C.A., Fisher, C.J., Bartek, J., Vojtesek, B., Lane, D., and Barnes, D.M. (1992). 
Analysis of p53 expression in human tumors: an antibody raised against human p53 
expressed in Escherichia coli. J. Cell Sci. 101, 183-189. 
Pinhero, R., Liaw, P., Bertens, K., and Yankulov, K. (2004). Three cyclin-dependent 
kinases preferentially phosphorylate different parts of the C-terminal domain of the large 
subunit of RNA polymerase II. Eur. J. Biochem. 271, 1004-1014. 
Price, D.H. (2000). P-TEFb, a cyclin-dependent kinase controlling elongation by RNA 
polymerase II. Mol. Cell. Biol. 20, 2629-2634. 
Radhakrishnan, S.K., and Gartel, A.L. (2006). A novel transcriptional inhibitor induces 
apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res. 66, 3264-3270. 
Ramanathan, Y., Rajpara, S.M., Reza, S.M., Lees, E., Shuman, S., Mathews, M.B., and 
Pe'ery, T. (2001). Three RNA polymerase II carboxyl-terminal domain kinases display 
distinct substrate preferences. J. Biol. Chem. 276, 10913-10920. 
Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S., and Bonner, W.M. (1998). DNA 
double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. 
Chem. 273, 5858-5868. 
Schimmer, A.D. (2004). Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into 
Clinical Practice. Cancer Res. 64, 7183-7190. 
Shapiro, G.I., and Harper, J.W. (1999). Anticancer drug targets: cell cycle and 
checkpoint control. J. Clin. Investig. 104, 1645-1653. 
Sims, R.J., Mandal, S.S., and Reinberg, D. (2004). Recent highlights of RNA-polymerase-
II-mediated transcription. Curr. Opin. Cell Biol. 16, 263-271. 
 22 
Song, L., Coppola, D., Livingston, S., Cress, D., and Haura, E.B. (2005). Mcl-1 Regulates 
Survival and Sensitivity to Diverse Apoptotic Stimuli in Human Non-Small Cell Lung 
Cancer Cells. Cancer Biol. Ther. 4, 267-276. 
Wang, S., and Fischer, P.M. (2008). Cyclin-dependent kinase 9: a key transcriptional 
regulator and potential drug target in oncology, virology and cardiology. Trends 
Pharmacol. Sci. 29, 302-313. 
Wang, S., Griffiths, G., Midgley, C., Meades, C., O'Boyle, J., Gibson, D., Wood, G., 
Grabarek, J., Cooper, M., Mezna, M., Jackson, W., Perry, A., Stuart, I., McClue, S.J., 
McInnes, C., Thomas, M., Yuill, R., Westwood, R., Lane, D.P., Jackson, R.C., and Fischer, 
P.M. (2005). Discovery and evaluation of CDK transcriptional inhibitors as anti-cancer 
agents. Proc. Am. Assoc. Cancer Res. 46, Abs. LB-110. 
Wang, S., Meades, C., Wood, G., Osnowski, A., Anderson, S., Yuill, R., Thomas, M., 
Mezna, M., Jackson, W., Midgley, C., Griffiths, G., Fleming, I., Green, S., McNae, I., Wu, 
S.-Y., McInnes, C., Zheleva, D., Walkinshaw, M.D., and Fischer, P.M. (2004a). 2-Anilino-
4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-Ray 
Crystallography, and Biological Activity. J. Med. Chem. 47, 1662-1675. 
Wang, S., Midgley, C.A., Scaerou, F., Grabarek, J.B., Griffiths, G., Jackson, W., 
Kontopidis, G., McClue, S.J., McInnes, C., Meades, C., Mezna, M., Plater, A., Stuart, I., 
Thomas, M.P., Wood, G., Clarke, R.G., Blake, D.G., Zheleva, D.I., Lane, D.P., Jackson, 
R.C., Glover, D.M., and Fischer, P.M. (2010). Discovery of N-Phenyl-4-(thiazol-5-
yl)pyrimidin-2-amine Aurora Kinase Inhibitors. J. Med. Chem. 53, 4367-4378. 
Wang, S., Wood, G., Meades, C., Griffiths, G., Midgley, C., McNae, I., McInnes, C., 
Anderson, S., Jackson, W., Mezna, M., Yuill, R., Walkinshaw, M., and Fischer, P.M. 
(2004b). Synthesis and Biological Activity of 2-Anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK 
Inhibitors. Bioorg. Med. Chem. Lett. 14, 4237-4240. 
Wu, S.Y., McNae, I., Kontopidis, G., McClue, S.J., McInnes, C., Stewart, K.J., Wang, S., 
Zheleva, D.I., Marriage, H., Lane, D.P., Taylor, P., Fischer, P.M., and Walkinshaw, M.D. 
(2003). Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: 
Structural Basis for Ligand-Induced Disordering of the Activation Loop. Structure 11, 
399-410. 
Zangemeister-Wittke, U., and Simon, H.-U. (2004). An IAP in action: the multiple roles of 
survivin in differentiation, immunity and malignancy. Cell Cycle 3, 1121-1123. 
Zhang, C., Lundgren, K., Yan, Z., Arango, M.E., Price, S., Huber, A., Higgins, J., Troche, 
G., Skaptason, J., Koudriakova, T., Nonomiya, J., Yang, M., O'Connor, P., Bender, S., 
Los, G., Lewis, C., and Jessen, B. (2008). Pharmacologic properties of AG-012986, a 
pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol. Cancer Ther. 7, 818-
828. 
Zhou, M., Halanski, M.A., Radonovich, M.F., Kashanchi, F., Peng, J., Price, D.H., and 
Brady, J.N. (2000). Tat modifies the activity of CDK9 to phosphorylate serine 5 of the 
RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 
1 transcription. Mol. Cell. Biol. 20, 5077-5086. 
 
 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
1 
Supplemental information 
 
 
Discovery and characterisation of 2-anilino-4-(thiazol-5-
yl)pyrimidine transcriptional CDK inhibitors as anticancer 
agents 
Shudong Wang,1,2 Gary Griffiths,1 Carol A. Midgley,1 Anna L. Barnett,1 Michael Cooper,1 
Joanna Grabarek,1 Laura Ingram,1 Wayne Jackson,1 George Kontopidis,1,3 Steven J. 
McClue,1 Campbell McInnes,1,4 Janice McLachlan,1 Christopher Meades,1 Mokdad Mezna,1 
Iain Stuart,1 Mark P. Thomas,1 Daniella I. Zheleva,1 David P. Lane,1 Robert C. Jackson,1 
David M. Glover,1 David G. Blake,1,* and Peter M. Fischer1,2,* 
 
1Cyclacel Limited, Dundee DD1 5JJ, Scotland, UK 
2Present address: School of Pharmacy and Centre for Biomolecular Sciences, University 
of Nottingham, Nottingham NG7 2RD, UK 
3Present address: Veterinary School, University of Thessaly, Karditsa 43100, Greece 
4Present address: South Carolina College of Pharmacy, University of South Carolina, Co-
lumbia, SC 29208, USA 
*Correspondence: dblake@cyclacel.com (D.G.B), peter.fischer@nottingham.ac.uk (P.M.F) 
 
 
 
Table of contents 
Table S1 (related to Table 1). In vitro kinase selectivity of compound 14. p. 2 
Table S2 (related to Table 1). Biopharmaceutical and pharmacokinetic proper-
ties of compound 14. 
p. 2 
Table S3 (related to Table 1). Antiproliferative activity of compound 14. p. 3 
Table S4 (related to Figure 3). Selective induction of apoptosis in transformed 
cells by CDK9-selective compounds. 
p. 3 
Table S5 (related to Figure 4). Data collection and refinement statistics for X-
ray crystal structure complexes of CDK2 with compounds 11 and 14. 
p. 4 
Figure S1 (related to Figure 1). Identification of CDK transcriptional inhibitors 
by cell-based assays. 
p. 5 
Figure S2 (related to Figure 1). Induction of histone H2AX phosphorylation.  p. 6 
Figure S3 (related to Table 1). Human kinase assay panel for compound 14. p. 7 
Figure S4 (related to Figure 5). Cellular effects of CDK9-selective compounds.  p. 8 
Figure S5 (related to Table 1). In vivo antitumour activity of compound 14 in 
the murine P388/0 survival model. 
p. 8 
Figure S6 (related to Table 1). In vivo antitumour activity of compound 14 in 
the Colo-205 xenograft model.  
p. 9 
Supplemental Experimental Procedures p. 10 
Supplemental References p. 15 
 
Supplemental Text and Figures
2 
Table S2 (related to Table 1). In vitro kinase selectivity of compound 14. 
Kinase IC50 (μM)
a 
Bcr-Abl 4.4 ± 0.2 
Akt/PKB > 10 
CaMKII > 10 
CK2 > 10 
ERK-2 > 10 
GSK3b 0.39 ± 0.04 
Lck 1.9 ± 0.1 
PDGFb 0.80 ± 0.09 
Plk1 > 10 
PKA > 10 
PKC > 10 
S6 8.6 ± 3.7 
SAPK2a > 10 
Src 2.0 ± 0.1 
VEGFR2 0.18 ± 0.02 
Aurora A 0.65 ± 0.06 
Aurora B 0.40 ± 0.13 
a Mean ± SD of at least two independent determinations; [ATP] = 0.1 mM. 
Table S2 (related to Table 1). Biopharmaceutical and pharmacokinetic properties of 
compound 14. 
In vitro biopharmaceutical properties 
Partition coefficient LogD7.4
a 1.1 
Dissociation constants pKa
b 8.3, 3.1 
Aqueous solubilityc > 100 μM 
Intestinal permeability Papp
d (10-6 cm/s)  2.4 
Microsomal stabilitye 
CLint (mL/min/mg) 27.5 
t1/2
 (min) 50 
Plasma protein bindingf 
Fraction bound 
(%) 
64 
Rat pharmacokinetics 
Pharmacokinetic parameter 5 mg/kg iv 50 mg/kg po 
Exposure AUC0-24h (h.μM) 1.5 10.4 
Elimination t1/2 (h) 1.0 4.9 
Clearance  CL (L/h/kg) 8.7 12.2 
Volume of distribution  Vz-F (L/kg) 126 97 
Oral bioavailability  (% F)  70 
a Partitioning between octanol and aqueous buffer using the shake-flask method; b de-
termined using a pH-metric method; c by turbidimetry; d apparent permeability coefficient 
measured using a Caco-2 cell layer assay; e measured by disappearance of parent com-
pound (LC-MS) from a preparation of rat liver microsomes; f rat plasma protein binding 
using an equilibrium dialysis assay. 
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Table S3 (related to Table 1). Antiproliferative activity of compound 14. 
Human cell line 72-h MTT 
IC50 ± SD (nM) 
T
ra
n
s
fo
rm
e
d
 
Origin Designation 
Bone osteosarcoma 
Saos-2 386 ± 189 
U2OS 372 ± 69 
Breast 
MDA-MB-468 221 ± 56 
MCF-7 490 ± 358 
Cervix Hela 401 ± 154 
Colon 
HT29 280 ± 73 
LOVO 218 ± 118 
NCI-H1299 501 ± 207 
HCT-116 180 ± 44 
Gastric adenocarcinoma AGS 256 ± 104 
Leukemia CCRF-CEM 577 ± 438 
Promyelocytic leukaemia HL60 374 ± 25 
Lung 
A549 299 ± 93 
NCI-H460 264 ± 146 
Leiomyosarcoma 
SKUT-1B 107 ± 43 
SKUT-1 225 ± 75 
Neuroblastoma SK-N-MC 149 ± 24 
Ovarian carcinoma A2780 131 ± 9 
Pancreatic carcinoma Mia-Paca-2 139 ± 9 
Prostate DU-145 140 ± 17 
Skin keratinocyte Hacat 351 ± 122 
Uterine 
Messa 150 ± 16 
Messa-Dx5 536 ± 260 
Untransformed Foetal lung fibroblast 
IMR-90 12,278 ± 1,422 
WI38 5,748 ± 3,123 
Mean transformed 293 
Median transformed 264 
Mean untransformed 9013 
 
Table S4 (related to Figure 3). Selective induction of apoptosis in transformed cells by 
CDK9-selective compounds. 
Treatment % Cells TUNEL-positivea 
Test compound Concentration (μM) 
A2780 
(Transformed) 
WI-38 
(Untransformed) 
Compound 3 
0.2 8 NT 
1.0 63 3 
Compound 9 
1.0 6 NT 
5.0 69 17 
Compound 10 
1.0 2 NT 
5.0 53 10 
Control 1 0 
a TUNEL analysis of treated cells. A2780 or cycling WI-38 cells were treated with com-
pounds for 24 h. Cells were analysed for DNA strand breaks by the TUNEL method. The 
percentages of cells labelled as TUNEL-positive are shown. All compounds show a greater 
selectivity for the transformed line over the untransformed one. NT-not tested. 
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Table S5 (related to Figure 4). Data collection and refinement statistics for X-ray crys-
tal structure complexes of CDK2 with compounds 11 and 14. 
Data collection CDK2-compound 11 CDK2-compound 14 
Space group P212121 P212121 
Unit cell dimensions; a, b, c (Å) 53.12, 71.50, 71.64 53.00, 71.11, 72.03 
Maximum resolution (Å) 1.9 1.8 
Total observations 67,708 67,264 
Unique reflections 21,623 25,565 
Completeness (%) 97.9 98.8 
Rmerge 0.078 0.075 
<I / σ I> 7.9 7.3 
Rmerge, highest resolution bin 0.415 0.485 
<I / σ I>, highest resolution bin 2.3 2.1 
Refinement   
Protein atoms 2,404 2,487 
Ligand atoms 58 54 
Water molecules 255 271 
Reflections used in refinement 20,724 22,796 
Rwork 18.9 21.1 
Rfree 27.1 29.5 
Mean B-factor, protein (Å2) 52.1 48.8 
Mean B-factor, ligands (Å2) 57.8 40.2 
Mean B-factor, solvent (Å2) 58.5 53.4 
Bond lengths from ideal values 
RMSD (Å) 
0.011 0.012 
Bond angles from ideal values  
RMSD (degrees) 
1.69 1.60 
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Figure S1 (related to Figure 1). Identification of CDK transcriptional inhibitors 
by cell-based assays. Cells were treated with a set of 220 test compounds from our 2-
anilino-4-(heteroaryl)pyrimidine kinase inhibitor compound library (Wang et al., 2004a; 
Wang et al., 2004b; Wu et al., 2003) or assay diluent only (DMSO control) at 10 µM for 7 
h. MI was measured by determining the percentages of phospho-histone-H3 positive U2-
OS cells. Nuclear accumulation of p53 was assessed by immunofluorescent staining in 
MCF-7 cells. Phenotypic classification is indicated: unclassified; class 1 (transcriptional 
inhibitors); class 2 (mitotic inhibitors); class 3 (cell cycle inhibitors). 
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Figure S2 (related to Figure 1). Induction of histone H2AX phosphorylation. 
Compound 1 does not induce phosphorylation of histone H2AX, (a classical marker of 
DNA damage) at early time points in contrast to the DNA damaging agent doxorubicin. 
Cells were treated with compounds or assay diluent only (control) at the concentrations 
indicated for 7 h. 
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Figure S3 (related to Table 1). Human kinase assay panel for compound 14. The 
assays were carried out using appropriate protein or peptide substrates and at ATP con-
centrations near the Km,ATP for the individual kinases (5 – 50 μM). 
8 
 
Figure S4 (related to Figure 5). Cellular effects of CDK9-selective compounds. 
A2780 cells were treated with compounds 3, 9 and 10 for 3 hours. These compounds 
represent molecules with a greater selectivity for CDK9 over CDK7 compared to 14. Each 
compound can reduce the phosphorylation of RNAP-II CTD at Ser-2, induce p53, and re-
duce levels of Mcl-1. 
 
 
 
 
 
 
 
 
 
Figure S5 (related to Table 1). In vivo antitumour activity of compound 14 in 
the murine P388/0 survival model. Groups of animals were dosed ip with compound 
14 twice daily for ten days. 
9 
 
Figure S6 (related to Table 1). In vivo antitumour activity of compound 14 in 
the Colo-205 xenograft model. Compound 14 was administered once daily for 8 days. 
The positive control chemotherapy agent 5-FU was given using an optimal dose and 
schedule for the Colo-205 model. Tumour versus control ratios (% T/C) on days 29, 32 
and 36: 85, 75 and 62% (5-FU); 45, 36 and 35% (14, 50 mg/kg ip); 49, 41 and 38% 
(14, 100 mg/kg po). Maximal growth delay (T – C) was 15 days (14, 50 mg/kg ip) and 
12 days (14, 100 mg/kg po). 
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Supplemental Experimental Procedures 
Synthesis and compound characterisation 
3-[4-(2-Ethylamino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide 
(2). By condensation of 3-dimethylamino-1-(2-ethylamino-4-methyl-thiazol-5-yl)-
propenone and nitrate of 3-guanidino-benzenesulfonamide. Yellow solid; mp: 148-150 
°C; anal. RP-HPLC (0-60% MeCN): tR = 13.1 min; 
1H-NMR (500 MHz, DMSO-d6): δ 1.18 
(t, J = 7.5 Hz, 3H), 2.48 (s, 3H), 3.27 (m, 2H), 6.94 (d, J = 6.0 Hz, 1H), 7.39 (m, 1H), 
7.45 (m, 1H), 7.94 (m, 1H), 8.10 (m, 2H), 8.32 (s, 1H), 8.35 (d, J = 5.5 Hz, 1H), 9.74 
(s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.98, 19.39, 108.13, 116.27, 117.98, 118.89, 
122.22, 129.64, 141.78, 145.19, 153.46, 158.25, 159.48, 159.96, 169.45; HRMS (m/z): 
[M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 391.1007. 
3-[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide 
(3). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-thiazol-5-yl)-
propenone and nitrate of 3-guanidino-benzenesulfonamide. Yellow solid; mp: 276-278 
°C; anal. RP-HPLC (0-60% MeCN): tR = 11.8 min; 
1H-NMR (500 MHz, DMSO-d6): δ 2.73 
(s, 3H), 3.12 (d, , J = 5.0 Hz, 3H), 7.20 (d, J = 6.0 Hz, 1H), 7.52 (s, 2H), 7.65 (d, J = 
8.0 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.29 (m, 1H), 8.59 (br s, 
1H), 8.61 (d, J = 6.0 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.8, 31.9, 107.98, 
112.50, 116.33, 118.32, 119.01, 122.22, 129.64, 141.77, 145.20, 153.52, 158.28, 
159.45, 159.95; HRMS (m/z): [M+H]+ calcd for C15H17N6O2S2, 377.0854; found, 
377.0857. 
N-Methyl-3-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-benzene-
sulfonamide (4). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-
thiazol-5-yl)-propenone and nitrate of 3-guanidino-N-methyl-benzenesulfonamide. Yellow 
solid; mp: 243-245 °C; anal. RP-HPLC (0-60% MeCN): tR = 13.2 min; 
1H-NMR (500 MHz, 
DMSO-d6): δ 2.53 (s, 3H), 2.57 (d, J = 5.0 Hz, 3H), 2.99 (s, 3H), 7.00 (d, J = 5.5 Hz, 
1H), 7.44 (d, J = 8.0Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 8.33 (d, 
J = 5.5 Hz, 1H), 8.52 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.34, 29.46, 31.63, 
108.08, 117.12, 118.29, 119.51, 122.66, 129.89, 140.35, 142.01, 153.54, 158.28, 
159.40, 159.87, 170.47. HRMS (m/z): [M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 
391.1007. 
3-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-N-methyl-benzenesulfon-
amide (5). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-dimethylamino-
propenone and nitrate of 3-guanidino-N-methyl-benzenesulfonamide. Yellow solid; mp: 
206-208 °C; anal. RP-HPLC (0-60% MeCN: tR = 15.9 min; 
1H-NMR (500 MHz, DMSO-d6): 
δ 2.43 (s, 3H), 2.44 (s, 3H), 7.14 (d, J = 5.5 Hz, 1H), 7.35 (m, 1H), 7.52 (t, J = 8.0 Hz, 
1H), 7.98 (d, J = 8.0 Hz, 1H), 8.30 (s, 1H), 8.58 (d, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, 
DMSO-d6): δ 18.54, 19.65, 29.43, 109.85, 117.40, 119.91, 122.89, 130.02, 131.14, 
140.40, 141.65, 152.98, 158.74, 160.07, 167.22; HRMS (m/z): [M]+ calcd for 
C15H16N6O2S2, 376.0776; found, 376.0774. 
(3-Methanesulfonyl-phenyl)-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-
amine (6). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-thiazol-5-
yl)-propenone and N-(3-methanesulfonyl-phenyl)-guanidine nitrate. Light yellow solid; 
mp: 272-274 °C; anal. RP-HPLC (0-60% MeCN): tR = 13.8 min; 
1H-NMR (500 MHz, 
DMSO-d6): δ 2.86 (s, 3H), 2.87 (s, 3H), 3.20 (s, 3H), 6.98 (d, J = 5.5 Hz, 1H), 7.46 (d, J 
= 7.5 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.95 (m, 1H), 8.08 (m, 1H), 8.38 (d, J = 5.0 Hz, 
1H), 8.54 (s, 1H), 9.87 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.33, 31.69, 44.47, 
108.11, 116.72, 118.29, 119.77, 123.78, 130.15, 141.87, 142.24, 153.64, 158.37, 
159.29, 159.78, 161.53; HRMS (m/z): [M+H]+ calcd for C16H18N5O2S2, 376.0902; found, 
376.0902. 
[4-(2-Ethylamino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-methanesulfonyl-phenyl)-
amine (7). By condensation of 3-dimethylamino-1-(2-ethylamino-4-methyl-thiazol-5-yl)-
11 
propenone and N-(3-methanesulfonyl-phenyl)-guanidine nitrate. Light yellow solid; mp: 
220-221 °C; anal. RP-HPLC (0-60% MeCN): tR = 14.6 min; 
1H-NMR (500 MHz, DMSO-
d6): δ 1.19 (t, J = 7.0 Hz, 3H), 2.48 (s, 3H), 2.63-3.17 (m, 5H), 6.97 (d, J = 5.5 Hz, 
1H), 7.47 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.94 (m, 1H), 8.16 (m, 1H), 8.38 
(d, J = 5.0 Hz, 1H), 8.51 (s, 1H), 9.86 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.93, 
19.36, 44.48, 46.00, 108.19, 116.74, 117.94, 119.78, 123.80, 130.17, 141.87, 142.27, 
153.60, 158.34, 159.35, 159.80, 169.51; HRMS (m/z): [M+H]+ calcd for C17H20N5O2S2, 
390.1058; found, 390.1060. 
3-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-N-ethyl-benzenesulfon-
amide (8). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-dimethylamino-
propenone and nitrate of N-ethyl-3-guanidino-benzenesulfonamide. Yellow solid; mp: 
176-177 °C; anal. RP-HPLC (0-60 % MeCN%): tR = 13.5 min; 
1H-NMR (500 MHz, DMSO-
d6): δ 1.08 (t, J = 7.5 Hz, 3H), 2.51 (s, 3H), 2.95 (m, 2H), 6.98 (d, J = 5.5 Hz, 1H), 
7.44-7.49 (m, 2H), 7.89 (d, J = 7.5 Hz, 1H), 8.34 (d, J = 5.5 Hz, 1H), 8.37 (br s, 1H); 
HRMS (m/z): [M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 391.1007. 
[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-[4-methyl-3-(morpholine-4-
sulfonyl)-phenyl]-amine (9). By condensation of 3-dimethylamino-1-(4-methyl-2-
methylamino-thiazol-5-yl)-propenone and N-[4-methyl-3-(morpholine-4-sulfonyl)-
phenyl]-guanidine nitrate. Light yellow solid; mp: 237-238 °C; anal. RP-HPLC (0-60% 
MeCN): tR = 15.8 min; 
1H-NMR (500 MHz, DMSO-d6): δ 2.53 (s, 3H), 2.59 (s, 3H), 2.99 
(s, 3H), 3.16 (m, 4H), 3.70 (m, 4H), 6.97 (d, J = 5.5 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
7.80 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H); 13C-NMR (125 MHz, 
DMSO-d6): δ 19.38, 20.38, 31.61, 46.03, 66.30, 108.02, 118.29, 119.89, 123.51, 
129.75, 133.71, 135.34, 139.74, 153.47, 158.27, 159.50, 159.94, 170.38. HRMS (m/z): 
[M+H]+ calcd for C20H25N6O3S2, 461.1430; found, 461.1433. 
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-methyl-3-(morpholine-4-
sulfonyl)-phenyl]-amine (10). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-
dimethylamino-propenone and N-[4-methyl-3-(morpholine-4-sulfonyl)-phenyl]-guanidine 
nitrate. Light yellow solid; mp: 183-184 °C; anal. RP-HPLC (0-60% MeCN): tR = 15.5 
min. 1H-NMR (500 MHz, DMSO-d6): δ 2.76 (s, 3H), 2.82 (s, 3H), 3.38 (m, 4H), 3.95 (m, 
4H), 7.23 (d, J = 5.5 Hz, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.83 (s, 2H), 8.41 (m, 1H), 8.66 
(d, J = 5.0 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.16, 20.33, 46.03, 66.32, 
108.31, 118.33, 120.11, 123.47, 129.70, 133.66, 135.41, 139.72, 153.12, 158.24, 
159.63, 159.95, 169.62. HRMS (m/z): [M+H]+ calcd for C19H23N6O3S2, 447.1273; found  
447.1271. 
4-[4-(3,4-Dimethyl-2-oxo-2,3-dihydro-thiazol-5-yl)-pyrimidin-2-ylamino]-N-(2-
methoxy-ethyl)-benzenesulfonamide (11). By condensation of 5-(3-dimethylamino-
acryloyl)-3,4-dimethyl-3H-thiazol-2-one and nitrate of 4-guanidino-N-(2-methoxy-ethyl)-
benzenesulfonamide; Yellow solid; mp: 238-239 °C; anal. RP-HPLC (0-60% MeCN): tR = 
16.3 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.52 (s, 3H), 2.82 (q, J = 6.0, 12.0 Hz, 2H), 
3.10 (s, 3H), 3.23 (m, 2H), 3.25 (s, CH3), 7.00 (d, J = 5.5 Hz, 1H), 7.43 (t, J = 6.0 Hz, 
1H), 7.64 (d, J = 9.0 Hz, 2H), 7.87 (d, J = 9.0 Hz, 2H), 8.44 (d, J = 5.5 Hz, 1H); 13C-
NMR (125 MHz, DMSO-d6): δ 15.02, 30.35, 42.83, 58.56, 71.25, 110.08, 110.24, 
118.85, 128.12, 133.08, 139.03, 144.63, 158.61, 159.30, 159.77, 170.37; HRMS (m/z): 
[M+H]+ calcd for C18H22N5O4S2, 436.1113; found 436.1111. 
3-[4-(3,4-Dimethyl-2-oxo-2,3-dihydro-thiazol-5-yl)-pyrimidin-2-ylamino]-benzonitrile 
(12). By treatment of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one and 
N-(3-cyano-phenyl)-guanidine nitrate; anal. RP-HPLC (10-70% MeCN): tR = 15.5 min; 
1H-NMR (500 MHz, DMSO-d6): δ 2.52 (s, 3H), 3.29 (s, 3H), 7.06 (d, J = 5.5 Hz, 1H), 
7.40 (m, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.93 (m, 1H), 8.33 (s, 1H), 8.50 (d, J = 5.5 Hz, 
1H), 10.00 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.97, 30.32, 109.94, 109.95, 
112.05, 119.76, 121.89, 124.04, 125.43, 130.61, 139.02, 141.91, 158.55, 159.34, 
159.78, 170.36; HRMS (m/z): [M+H]+ calcd for C16H14N5OS, 324.0919; found 324.0927. 
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3,4-Dimethyl-5-[2-(4-methyl-3-nitro-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one 
(13). By condensation of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one 
and N-(3-cyano-4-methyl-phenyl)-guanidine nitrate; anal. RP-HPLC (10-70% MeCN): tR 
= 17.6 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.44 (s, 3H), 2.55 (s, 3H), 3.28 (s, 3H), 
7.03 (d, J = 5.5 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 8.48 (d, J = 
5.5 Hz, 1H,), 8.59 (s, 1H), 9.99 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.96, 19.70, 
30.32, 109.79, 114.22, 124.13, 125.63, 133.42, 138.94, 140.07, 149.44, 158.54, 
159.33, 159.80, 170.41; HRMS (m/z): [M+H]+ calcd for C16H16N5O3S, 358.0974; found, 
358.0976. 
3,4-Dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one 
(14). A solution of potassium thiocyanate (5.67 g, 58 mmol) in Me2CO (45 mL) was 
cooled on ice and 3-chloro-pentane-2,4-dione (6.95 mL, 58 mmol) was added dropwise. 
The mixture was warmed to room temperature and stirred for 6 h. After evaporation to 
dryness, the residue was dissolved in EtOH (30 mL) and conc. aq HCl (15 mL) was 
added. This mixture was heated to reflux for 14 h. After cooling, it was concentrated and 
the resulting precipitates were filtered and washed successively with cold MeOH and Et2O 
to afford 5-acetyl-4-methyl-3H-thiazol-2-one (9.1 g, 100%). mp 208-211 °C; anal. RP-
HPLC (10-70% MeCN): tR = 6.5 min; 
1H-NMR (500 MHz, CDCl3): δ 2.33 (s, 3H), 2.38 (s, 
3H), 11.9 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 15.06, 29.94, 115.53, 142.99, 
170.92, 189.91; FTIR: 3094, 2850, 1669, 1622, 1579 cm-1; MS (m/z): [M+H]+ calcd for 
C6H8NO2S, 158.19; found 157.77. 
5-Acetyl-4-methyl-3H-thiazol-2-one (4.64 g, 27.1 mmol) and N,N-dimethylformamide 
dimethylacetal (8.4 mL, 59.6 mmol) were mixed in a dry, Ar-flushed flask, and the mix-
ture was heated at 100 °C for 3 h. After cooling, an equal volume of Et2O was added. The 
resulting orange solid was filtered and washed with Et2O to afford 2.73 g of 5-(3-
dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one as an orange solid. 1H-NMR (500 
MHz, DMSO-d6): δ 2.52 (s, 3H), 2.82 (br s, 3H), 3.11 (br s, 3H), 3.22 (s, 3H), 5.10 (d, J 
= 12.2Hz, 1H,), 7.61 (d, J = 11.7 Hz, 1H). 
N-[4-(4-Acetyl-piperazin-1-yl)-phenyl]-guanidine nitrate was prepared following the 
procedures described previously (Wang et al., 2004a). The reaction mixture was filtered 
through Celite and concentrated under reduced pressure. Recrystallisation from EtOH 
gave the pure product as a pale pink solid (91%). 1H-NMR (500 MHz, DMSO-d6): δ 2.06 
(s, 3H), 3.15 (m, 4H), 3.58 (m, 4H), 7.04-7.19 (m, 8H), 9.32 (s, 1H). 
A solution of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one (0.20 g, 0.88 
mmol), N-[4-(4-acetyl-piperazin-1-yl)-phenyl]-guanidine nitrate (0.38 g, 1.15 mmol) and 
NaOH (0.09 g, 2.3 mmol) in 2-methoxylethanol (15 mL) was heated at 120 °C for 20 h. 
The reaction mixture was evaporated to dryness and the residue was purified by silica gel 
chromatography, eluting with CH2Cl2, then 2% MeOH/CH2Cl2 to afford 5-[2-[4-(4-acetyl-
piperazin-1-yl)-phenylamino]-pyrimidin-4-yl]-3,4-dimethyl-3H-thiazol-2-one as a yellow 
solid (0.22 g, 60 %). Mp. 231-234 °C; anal. RP-HPLC (10-70% MeCN): tR = 9.5 min; 
1H-
NMR (500 MHz, DMSO-d6): δ 2.03 (s, 3H), 2.55 (s, 3H), 3.01 (m, 2H), 3.08 (m, 2H), 
3.29 (s, 3H), 3.57 (m, 4H), 6.87 (d, J = 5.5 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 7.58 (d, J 
= 9.0 Hz, 2H), 8.37 (d, J = 5.5 Hz, 1H), 9.37 (s, 1H); Analysis (calcd, found for 
C21H24N6O2S): C (58.41, 58.49), H (5.70, 5.77), N (19.80, 19.33). 
This material, in 2 M HCl in EtOH, was heated under reflux for 2.5 h. After cooling, the 
mixture was evaporated, the residue was basified by addition of 2 M aq NaOH and ex-
tracted (2 × 50 mL CH2Cl2). The combined extracts were washed with brine, dried on 
MgSO4, and filtered. The solvent was evaporated and the residue was crystallised from 
MeOH to afford 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-
thiazol-2-one (14) as a yellow solid (90%). mp. 224-226 °C; anal. RP-HPLC (0-60% 
MeCN): tR = 10.9 min; 
1H-NMR (500 MHz, DMSO-d6): δ 2.57 (s, 3H), 3.10 (m, 4H), 3.16 
(m, 4H), 3.36 (s, 3H), 6.65 (d, J = 5.5 Hz, 1H), 6.94 (d, J = 10.5 Hz, 2H), 7.47 (d, J = 
9.0 Hz, 2H), 8.31 (d, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.85, 30.20, 
46.35, 50.84, 108.18, 110.62, 116.36, 121.11, 132.83, 138.18, 147.69, 158.38, 159.13, 
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160.33, 170.42. Analysis (calcd, found for C19H22N6OS·0.45 H2O): C (59.55, 59.32), H 
(6.10, 6.14), N (25.59, 24.97). 
Cloning, expression, and purification of His-tagged CDK9/Cyclin T1 
Cloning and expression of His-tagged CDK9/cyclin T1. Baculoviral transfer vector 
pFastBac HTa (Invitrogen, Carlsbad, USA) was modified to produce pSSP1, by replacing 
the region between the Rsr II and Eco RI restriction endonuclease sites of pFastBac HTa 
with a double stranded linker corresponding to sense strand 5’-GTCCGTCCGAAACCAT 
GTCGTACTACCATCACCATCACCATCACGGTATGGCTAGCGACGATGACGATAAGGGATCCGTGC
GGCCGCG-3’. This modification was introduced to allow expression of fusion proteins 
where the N-terminal polyhistidine tag (His-tag) could be removed by cleavage at an en-
tertokinase cleavage site introduced immediately adjacent to the polypeptide encoded by 
the inserted gene of interest. 
The CDK9 open reading frame was amplified from a human foetal lung 5’-Stretch Plus 
cDNA library (Clontech, Palo Alto, USA) using PCR primer 1 (5'-GCGTTGGAGGCGGCCATG 
GCAAAGCAGTACG-3’) and 2 (5’-CTAGTGGCAAGCGCCGGCCCTCAGAAG-3’). The amplified 
DNA fragment was cloned into pCR4-Topo (Invitrogen, Carlsbad, USA), to give pCR4-
CDK9. PCR primer 3 (5’-GGCGCTAGCGACGATGACGATAAGATGGCAAAGCAGTACGACTCG-
3’) and 4 (5’-CAGGAAACAGCTATGAC-3’) were used to amplify the CDK9 open reading 
frame from pCR4-CDK9. The PCR product generated was digested with Nhe I and Eco RI 
and ligated into pSSP1, also digested with Nhe I and Eco RI. Insert DNA from several 
clones was sequenced, and fragment exchange was used to generate a single clone, 
pSSP1-Cdk9 with the correct CDK9 coding sequence. 
The cyclin T1 open reading frame was amplified as two fragments from a human foetal 
lung 5’-Stretch Plus cDNA library (Clontech, Palo Alto, USA), using PCR primer 5 (5’-
ATGGAGGGAGAGAGGAAGAACAACAACAAACGGTGGTAT-3’) and 6 (5’-GTAAGTGCTAAATTC 
TCACTAGTCCG-3’), or PCR primer 7 (5’-CTACTCAGGG TCATCGGACT AGTGAG-3’) and 8 
(5’-TTACTTAGGAAGGGGTGGAAGTGGTGGAGGAGGTTCTGA-3’). Each of the PCR products 
generated were cloned into pCR4-Topo, giving pCR4-5’Cyclin T1 and pCR4-3’cyclin T1, 
respectively. The sequence of these PCR fragments was confirmed. The cyclin T1 frag-
ment of pCR4-5’cyclin T1 was then amplified using PCR primer 9 (5’-
GGCGCTAGCGACGATGACGATAAGATGGAGGGAGAGAGGAAGAACAAC-3’) and 4 (5-CAGGA 
AACAGCTATGAC-3’), to introduce an Nhe I restriction endonuclease site upstream of the 
Cyclin T1 coding sequence. The resulting PCR product was digested with Nhe I and Eco 
RI and then ligated into pSSP1, also digested with Nhe I and Eco RI, to give pSSP-
5’cyclin T1. The complete cyclin T1 open reading frame was subsequently generated by 
digesting pCR4-3’cyclin T1 with Not I and Spe I, and ligating the required fragment into 
pSSP-5’cyclin T1, also digested with Not I and Spe I, to create pSSP1-cyclin T1. 
Bacmid DNA and baculoviral stocks were generated from pSSP1-CDK9 and pSSP1-
cyclin T1 according to the manufacturer’s instructions for pFastBac HTa. High-titre bacu-
loviral stocks were generated by amplification in Sf9 cells grown in suspension culture. 
Viral titres were determined by standard plaque assay protocols, as per the manufac-
turer’s instructions. 
His-tagged CDK9 and cyclin T1 were co-expressed following co-infection of Sf9 cells by 
SSP1-CDK9 and SSP1-cyclin T1 baculoviruses. 72 h post-infection, cells were harvested 
by centrifugation, and snap frozen. Recombinant protein expression levels were con-
firmed by western blotting, using CDK9 sc-8338 and cyclinT1 sc-10750 antibodies (Santa 
Cruz Biotechnology, Inc., Santa Cruz, USA). 
Protein Purification. The Sf9 cell pellet from 300 mL cell culture was lysed in 30 mL of 
25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 270 mM sucrose, 1% Triton X-
100, 0.07% β-mercaptoethanol, 1 mM Na3VO4, 5 mM NaF, 0.2 mM PMSF, 1 mM ben-
zamidine, protease inhibitor cocktail (Sigma, St. Louis, USA ). After incubating on ice for 
20 min, the samples were cleared by centrifuging for 20 min at 15,000 rpm. The result-
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ing supernatant was supplemented with NaCl to 0.3 M, and then 1.2 mL (pre-
equilibrated) Ni-NTA beads were added. After 1.5 h constant rotation at 4 oC, samples 
were centrifuged for 2 min at 2,000 rpm and supernatant was removed. Beads were re-
suspended in 10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.5 M 
NaCl, 20 mM imidazole, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM 
benzamidine then and transferred to a 12 mL column. Washing was performed twice with 
10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.5 M NaCl, 20 mM imi-
dazole, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM benzamidine, 
and then twice with 10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.3 
M NaCl, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM benzamidine. 
CDK9/cyclin T1 was eluted with three washes of 2 mL of 25 mM HEPES pH 7.5, 0.02 mM 
EGTA, 0.02 mM EDTA, 0.3 M NaCl, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM 
PMSF, 1 mM benzamidine, 200 mM imidazole. CDK9/cyclin T1-containing fractions were 
identified by Western blotting. These fractions were combined and then dialysed over-
night against 100 volumes of 50 mM Tris/HCl pH7.5, 0.1 mM EGTA, 150 mM NaCl, 270 
mM sucrose, 0.03% Brij-35, 0.07% β-mercaptoethanol, 1 mM benzamidine, 0.1 mM 
PMSF. Protein concentration was determined by BCA assay. Samples were snap frozen in 
100 μL aliquots, and stored at -70 °C. Specific activity was determined prior to use in 
screening assays. 
Biopharmaceutical profiling and PK determinations 
Test compound partitioning between octanol and aqueous buffer was carried out using 
the shake-flask method (Dearden, 1985). Compound pKa values were determined using a 
pH-metric titration method (GlpKa; Sirius) (Comer, 2003). Aqueous solubility was as-
sessed by turbidimetric measurements (Brooker et al., 1974). Apparent permeability co-
efficients were measured using a Caco-2 cell layer assay (Gan et al., 1997). In vitro 
phase-I liver metabolism was assessed by disappearance of parent compound (LC-MS 
quantitation) from a preparation of rat liver microsomes (Houston et al., 1997). Rat 
plasma protein binding was determined in an equilibrium dialysis assay (Kariv et al., 
2001). 
For PK measurements 3 male Wistar rats per sample and dose were treated by iv bo-
lus injection or by po gavage of test compound solutions. Blood samples were collected 
from each rat from the cannulated jugular vein at time zero and at intervals up to 24 h. 
Samples were centrifuged immediately and plasma was harvested and frozen at –20 °C 
until analysis. Quantitative compound level analysis was carried out using LC-MS/MS 
methods. PK parameters were derived by the noncompartmental methods using the 
WinNonlin 3.2 software programme (Pharsight). Oral bioavailability (%F) was calculated 
by taking the ratio of dose-normalised AUC values from oral versus parenteral dosing. 
Evaluation of anti-tumour efficacy 
Murine P388/0 leukaemia model. Six-week-old male CD2F1 mice were implanted in-
traperitoneally with P388/0 leukaemia cells (105) on day 0. On day 1 post-inoculation 
mice were given by ip administration either vehicle or test compound (0.1 mL / 10 g 
body weight) at the dose shown, on a treatment schedule of twice a day for 10 days. The 
effectiveness of treatment was assessed by comparison of the median post-inoculation 
lifespan (ILS) of each group of treated mice with that of the vehicle control group. The 
ILS ratio of the treated and control groups was used as an indicator of efficacy. 
Colo-205 xenograft model. Female athymic ICR SCID mice, 5-6 weeks old on day 1 of 
the treatment, were used for this study. Test animal were implanted subcutaneously on 
day 0 with 30-60 mg tumour fragments using a 12-gauge trocar needle. Treatment be-
gan on day 18 when the mean estimated tumour mass for all groups in the study was 
107 mg (range 97-115 mg). The animals were assigned into the treatment and the con-
trol groups with 10 mice per group. All animals were observed for clinical signs at least 
once daily. Tumour size was measured at least twice weekly. Animals were terminated at 
any time during the study if the tumour size became excessive or any adverse effects 
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were noted. The treatments were administered by ip injection or po gavage daily, staring 
on day 18, and continuing for 8 days. The tumour burden (mg) was estimated from calli-
per measurements using the formula for the volume of a prolate ellipsoid assuming unit 
density. The mean tumour mass on the day of randomisation was reported for each 
group. Calculations of relative tumour mass and plot of mean tumour growth curves were 
performed. The relative tumour mass data from each group were compared using a one-
way analysis of variance (ANOVA) and statistical significance was determined using the 
built-in data analysis tools in Microsoft Excel and R (The R Project for Statistical Comput-
ing). 
Crystallography 
Human recombinant CDK2 was expressed, purified, and crystallised as previously de-
scribed (Wu et al., 2003). Data were collected at the Cyclacel home source with a FR-D 
X-ray generator using a Raxis IV++ image plate (Rigaku). Data processing was carried 
out using the d*TREK software suite (Pflugrath, 1999). The structures were solved by 
molecular replacement using MOLREP (Vagin et al., 1997) and PDB entry 1PW2. 
ARP/wARP (Lamzin et al., 1997) was used for initial density interpretation and the addi-
tion of water molecules. REFMAC (Murshudov et al., 1997) was used for structural re-
finement. A number of rounds of refinement and model building with the programme 
COOT (Emsley et al., 2010) were carried out. All the crystallographic programmes used 
were part of the CCP4 programme suite (Potterton et al., 2004). 
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